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deforming the sequential activity maps using registered 
sequential SPECT-CT scans and with the parallelogram 
method. In 9 out of 11 cases the Olinda/EXM calculations of 
average dose absorbed by the kidneys was below the dose 
calculated by Raydose (range [8,51]%). In 2 cases the kidney 
average dose, as calculated with the Olinda/EXM method, 
were below the dose calculated with Raydose (-6,-26)%. DVHs 
and 3D dose maps provided valuable information regarding 
the uniformity of the dose distribution which would have 
been otherwise missed with an organ level approach.  
Conclusions: Following the experience obtained in this pilot 
study we conclude that it is feasible to implement in routine 
delivery of PRRT therapy patient specific 3D dose calculation 
using Raydose. Our workflow included deformable image 
registration to accurately account for changes in both 
patients anatomy and activity distribution during the course 
of the therapy. Work is in progress to use Raydose to 
optimise PRRT treatments in terms of fractionation, 
combination of isotopes and correlation with toxicity data.  
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Purpose/Objective: A second generation 3D ultrasound 
image guidance (USIG) system (Clarity, Elekta Inc), which 
allows for transperineal (TP) localization and intra-fractional 
tracking of the prostate has been evaluated for use in 
stereotactic body radiation therapy (SBRT) of the prostate at 
our institution. Here we describe our implementation of a 
prostate SBRT TP USIG protocol.  
Materials and Methods: After the development of an initial 
clinical USIG based workflow for standard fractionation 
treatment, we extended the workflow to allow for increased 
positional verification required for SBRT. Our SBRT treatment 
protocol gives 36.25 Gy in 5 fractions, every other day and 
utilizes USIG to ensure target coverage. The planning target 
volume (PTV) is defined as the CTV plus a 3 mm margin 
posteriorly and 5 mm in all other dimensions.  Patient 
alignment has to be approved by a physicist and a physician, 
both of whom have to be experienced in reading US images. 
During intra-fractional US-tracking, corrective action is taken 
if the target migrates more than 3 mm for more than 5 
seconds in any of three orthogonal coordinates. Patients were 
positioned according to SBRT protocol and aligned to skin 
marks using treatment room lasers. TP USIG was performed 
and shifts from tattoo were performed and recorded. For 
purpose of redundant verification, a transabdominal (TA) 
USIG was performed (BAT, Nomos Inc.) while TP USIG 
tracking was on. Treatment was conducted using TP USIG 
tracking. 
Results: A total of 57 fractions delivered to 11 prostate 
cancer patients were retrospectively analyzed for workflow 
performance, patient motion and agreement between two US 
image guidance devices (TA and TP). The mean of initial USIG 
shifts from skin marks based on TP positioning for all 11 
patients was 0.24, 1.25, and -4.38 mm in left-right (LR), 
anterior-posterior (AP), and superior-inferior (SI) directions 
respectively. The average difference between the two US 
systems (TP vs TA) for all patients was -0.05, -0.02, and -0.04 
mm in LR, AP and SI directions respectively. The respective 
standard deviations were 0.14, 0.34 and 0.27 mm. Patient 
alignment was corrected if indicated by tracking. Intra-
fractional tracking data was analyzed and will be presented 
(see Image 1). 
 
 
 
Conclusions: 11 prostate SBRT patients treated in our clinic 
were localized using two USIG systems which showed average 
agreement to less than 0.5 mm in all three principle 
directions (LR, AP, SI). Intra-fraction tracking allowed us to 
reduce treatment planning margins to 3 mm posteriorly and 5 
mm elsewhere, due to the ability to track and correct for 
motion during treatment. 
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Purpose/Objective: ProtecT is a phase 3 clinical trial [1] 
comparing prostate cancer mortality for patients with 
clinically localised prostate cancer randomly assigned to 
active monitoring, radical prostatectomy or 3D conformal 
external beam radiotherapy.  
Trial results are anticipated for 2016 and the purpose of this 
work is to assess the quality of treatment plans produced for 
participants randomised to receive radiotherapy. 
Materials and Methods: 545 of the participants, recruited 
across 9 UK cities were randomised to receive radiotherapy. 
3D conformal external beam radiotherapy was used to deliver 
74Gy to the isocentre in 2Gy fractions in 2 phases. During 
phase 1 a dose of 56Gy was prescribed to a target volume 
including prostate and seminal vesicles and during phase 2 a 
dose of 18Gy is prescribed to a target volume surrounding 
prostate only. To ensure consistency and comparability of 
radiotherapy between centres a detailed radiotherapy 
protocol was developed. To assess the quality of radiotherapy 
plans, 13 quantities were measured and a deviation recorded 
